BrainStorm (OTC.BB:BCLI) is a leading  developer of  stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. The Company is focused on developing NTF cells from the patient's own bone marrow in order to treat, Parkinson, ALS, and Spinal Cord Injury

The adult stem cells are used to create healthy NTF cells which produce and secrete neurotrophic factors, which are essential for the survival and outgrowth of neurons, and may become beneficial in neurodegenerative diseases. Patients treated with the Company’s NurOwn™ therapeutic cells are expected to enjoy a rapid recovery and much enhanced quality of life. BrainStorm's therapy has the potential to cure underlying pathology, rather than simply treat symptoms.
  
BrainStorm's management and scientific teams are passionately devoted to the Company's mission: regenerating the mind... in their lifetime.